
The effect of infusing DDAVP and cryoprecipitate either singly or in combination was studied in a patient with variant von Willebrand disease. Both DDAVP and cryoprecipitate caused only partial correction in the hemostatic defect when used as a single agent. A combination of DDAVP and cryoprecipitate induced a complete correction of the hemostatic defect as well as factor VIII related properties.
Male, von Willebrand Diseases, Factor VIII, Fibrinogen, Genetic Variation, Humans, Deamino Arginine Vasopressin, Drug Therapy, Combination, Infusions, Parenteral, Middle Aged
Male, von Willebrand Diseases, Factor VIII, Fibrinogen, Genetic Variation, Humans, Deamino Arginine Vasopressin, Drug Therapy, Combination, Infusions, Parenteral, Middle Aged
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 7 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Top 10% | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Top 10% |
